UCB agreed to acquire Neurona in a deal valued at up to $1.2 billion, aiming to broaden its epilepsy portfolio beyond small molecules. UCB said the acquisition helps diversify into a potentially one-off cell-therapy approach in early testing for a hard-to-treat form of epilepsy. The transaction underscores continued investor focus on curative-intent modalities in neuroscience, where competitive advantage increasingly comes from differentiated mechanisms rather than incremental dosing improvements. For UCB, the move adds a development-stage therapeutic option that could complement its existing seizure treatments while expanding its future pipeline options. With early program data still emerging, the strategic rationale centers on platform and modality expansion, with the acquisition serving as a near-term bet on higher-upside cell-therapy potential.